Growing demand for NASH therapeutics due to COVID-19 severity risk
It has been reported that various metabolic diseases are a factor in COVID-19 severity, and an increased risk for those with non-alcoholic liver disease (NASH/NAFLD) has also been reported. [Pawlotsky, J., Nat Rev Gastroenterol Hepatol,2020]
Since there are currently no approved medications for NAFLD/NASH, new drug candidates are being developed. However, with the reported critical risk after COVID-19 infection, the development of new drugs is now more urgent than ever.
For the development of new medicines, choosing an ideal model at the non-clinical stage makes a smooth progression to clinical trials possible.
Therefore, I would like to briefly introduce our proprietary STAM™ mouse model for NAFLD/NASH and its advantages, outlined below.
– Reproduces the same disease progression as seen in human NAFLD/NASH patients, from steatosis to inflammation, fibrosis, and HCC.
– Exhibits symptoms of high blood glucose, hyperlipidemia and type 2 diabetes.
– The NAFLD activity score, a clinical endpoint, and histological analysis of fibrosis are standard analysis items
– 15 compounds tested in the model are in Phase 2 clinical trials and up
For those currently developing drugs targeting liver diseases like cirrhosis and HCC, or those considering expanding the indications for existing drugs, why not consider the STAM™ model for your non-clinical research?
For more information on the STAM™ model or our other disease models, please